New York, United States, Jan.  22, 2025  (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this method may be traced to a single parental cell. Adcertis, Kadcyla, and other drugs belong to this category.

Download Free Sample Report PDF @ https://straitsresearch.com/report/antibody-drug-conjugates-market/request-sample

Market Dynamics

Increasing Incidence and Prevalence of Cancer Drives the Global Market

The rising incidence of cancer is one of the primary drivers of market expansion throughout the forecast period. According to the WHO, cancer is the second most common cause of death worldwide. The International Agency for Research on Cancer projects that there will be 21.9 million new cancer cases in 2025 and 24.6 million in 2030. The number of cancer cases worldwide has increased significantly during the past decade. Additionally, the rising frequency of cancer in emerging nations is driving a significant need for ADCs. According to GLOBOCAN, over 49.2% of all cancer cases worldwide were expected to be reported in Asia in 2020. Therefore, this region continues to be a significant untapped market for ADCs. The general rise in cancer incidence is projected to increase the number of patients undergoing treatment, increasing the need for early diagnosis and therapy.

Presence of a Strong Product Pipeline Creates Tremendous Opportunities

Antibody Drug Conjugates (ADCs) are a distinct class of medicines composed of an antibody chemically linked to a cytotoxic substance. The goal of conventional chemotherapy is to eliminate proliferating tumor cells rapidly. Unfortunately, it can also harm healthy growing cells, resulting in negative side effects. On the other hand, ADC is intended to increase therapy efficacy and decrease systemic toxicity. Seagen, Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, and Daiichi Sankyo are developing and marketing these medications. For instance, in October 2018, Takeda Pharmaceutical and Seagen, Inc. (formerly Seattle Genetics, Inc.) announced that phase 3 clinical trials of Adcetris for treating CD30-expressing peripheral T-cell lymphoma met the primary endpoint. AstraZeneca and Daiichi Sankyo teamed in July 2020 to develop and commercialize novel ADC medicines. This assisted AstraZeneca in expanding its ADC product line.

Regional Analysis

North America is the most significant shareholder in the global antibody drug conjugates market and is projected to grow at a CAGR of 21.3% during the forecast period. North America will likely significantly increase during the forecast period due to rising cancer rates and technological developments. Due to technological advancements in countries such as the United States, Canada, and Mexico, the region is witnessing significant growth. In terms of clinical data, North America is a well-developed region. The use of ADCs, which comprise the majority of the existing market, is considered. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals Inc. to produce antibody-drug conjugates and other cancer medications. In addition, the regional market is expanding due to the growing incidence of cancer. The American Cancer Society projects that 1.9 million new cancer cases will be detected in the United States in 2022. The market for antibody-drug conjugates is expected to expand in the United States during the forecast period due to the rising demand for cancer drugs and the increasing number of cancer patients.

Europe is anticipated to grow at a CAGR of 26.4% over the forecast period. Europe is the second largest market for antibody-drug conjugates worldwide. Antibody-drug conjugates are projected to benefit from Germany's high healthcare expenditures and expanding research institute population. Germany is anticipated to be one of Europe's most lucrative ADC markets. In addition, several German pharmaceutical companies are attempting to enter the ADC market by investing in R&D. For example, Heidelberg Pharma and Tubulis are developing new ADC therapies in the clinical and preclinical stages. Tubulis, a German biotech startup, raised USD 12.3 million in July 2021 to increase research on ADCs, namely to improve on the research that found linker chemistry to be more stable than the technology employed in ADCs such as Seagen's (formerly Seattle Genetics) Adcetris.

Ask for Customization @ https://straitsresearch.com/report/antibody-drug-conjugates-market/request-sample

Key Highlights

The global antibody drug      conjugates market size was valued at USD 11.84 billion in 2024 and      is projected to reach from USD 12.89 billion in 2025 to USD      25.38 billion by 2033, growing at a CAGR of 8.84% during the      forecast period (2025-2033).Based on technology, the      global antibody drug conjugates market is divided into non-cleavable      linkers, cleavable linkers, and linerless. The cleavable linkers      segment is responsible for the largest market share and is expected to      grow at a CAGR of 22.1% over the forecast period.Based on application, the      global antibody drug conjugates market is segmented into blood cancer,      breast cancer, urothelial cancer, and other cancers. The breast cancer      segment owns the highest market share and is projected to grow at a CAGR      of 24.7% during the forecast period.North America is the most      significant shareholder in the global antibody drug conjugates market and      is projected to grow at a CAGR of 21.3% during the forecast period.

Competitive Players

Seagen Inc. (previously Seattle Genetics Inc.)Takeda Pharmaceutical Company LimitedAstraZeneca PLCF. Hoffmann-La Roche LtdPfizer IncImmunoGen IncGilead Sciences IncDaiichi Sankyo Company Limited

Recent Developments

March 2023- ImmunoGen, Inc. (Nasdaq: IMGN)      awarded Vertex Pharmaceuticals (Vertex) (NYSE: VRTX) the license to      conduct research using ImmunoGen's ADC technology to identify novel      targeted conditioning agents for use with gene editing.

February 2023- AstraZeneca and KYM Biosciences      Inc. signed an      exclusive license agreement for CMG901, a potential first-in-class antibody-drug      conjugate (ADC) targeting Claudin 18.2, a potential therapeutic target in      gastric cancer. Under the terms of the license agreement, AstraZeneca will      be responsible for the global research, development, manufacturing, and      marketing of CMG901.

Segmentation

By Technology

Cleavable LinkerNon-Cleavable LinkerLinkerless

By Applications

Blood CancerBreast CancerUrothelial Cancer/Bladder CancerOthers

By Region

North AmericaEuropeAsia PacificMiddle East And AfricaLatin America

Get Detailed Market Segmentation @ https://straitsresearch.com/report/antibody-drug-conjugates-market/segmentation

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

Phone: +1 646 905 0080 (U.S.)

+44 203 695 0070 (U.K.)

Email: [email protected]

Follow Us: LinkedIn | Facebook | Instagram | Twitter